Anzeige
Meldung des Tages: Warum diese Aktie einer der großen Gewinner im neuen Goldzyklus sein könnte

Iovance Biotherapeutics Aktie News

Aktie
WKN:  A2DT49 ISIN:  US4622601007 US-Symbol:  IOVA Branche:  Biotechnologie Land:  USA
2,2505 €
+0,021 €
+0,94%
11:47:44 Uhr
Depot/Watchlist
Marktkapitalisierung *
808,46 Mio. €
Streubesitz
37,88%
KGV
-2,57
Index-Zuordnung
-

Iovance Biotherapeutics News

28.05.25 - PR Newswire
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
28.05.25 - PR Newswire
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit PR Newswire
27.05.25 - PR Newswire
IOVA Stock New: Contact Robbins LLP for Information About the Securities Fraud Class Action Against Iovance Biotherapeutics, Inc. and to Learn How to Be Lead Plaintiff for the Class
IOVA Stock New: Contact Robbins LLP for Information About the Securities Fraud Class Action Against Iovance Biotherapeutics, Inc. and to Learn How to Be Lead Plaintiff for the ...
27.05.25 - PR Newswire
IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action ...
27.05.25 - PR Newswire
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
27.05.25 - PR Newswire
Iovance Biotherapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVA
Iovance Biotherapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVA PR Newswire
26.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA PR Newswire
23.05.25 - PR Newswire
FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC Continues Lead Plaintiff Search for Iovance Biotherapeutics, Inc. (IOVA) Securities Fraud Class Action
FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC Continues Lead Plaintiff Search for Iovance Biotherapeutics, Inc. (IOVA) Securities Fraud Class Action PR ...
23.05.25 - PR Newswire
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
23.05.25 - PR Newswire
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
22.05.25 - PR Newswire
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit PR Newswire
22.05.25 - PR Newswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics PR Newswire
21.05.25 - PR Newswire
Iovance Biotherapeutics (IOVA) Faces Investor Lawsuit Over Growth Projections Following Stock Plunge - Hagens Berman
Iovance Biotherapeutics (IOVA) Faces Investor Lawsuit Over Growth Projections Following Stock Plunge - Hagens Berman PR Newswire
20.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA PR Newswire
20.05.25 - PR Newswire
Iovance Biotherapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVA
Iovance Biotherapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVA PR Newswire
19.05.25 - PR Newswire
IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action ...
19.05.25 - PR Newswire
Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) Seeking Recovery for Investors - Contact The Gross Law Firm
Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) Seeking Recovery for Investors - Contact The Gross Law Firm PR Newswire
19.05.25 - PR Newswire
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit PR Newswire
17.05.25 - PR Newswire
Iovance Shareholders Should Contact Shareholder Rights Firm Regarding Potential Legal Claims
Iovance Shareholders Should Contact Shareholder Rights Firm Regarding Potential Legal Claims PR Newswire
13.05.25 - PR Newswire
Iovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% - Hagens Berman
Iovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% - Hagens Berman PR Newswire

Newssuche

Videos

newspaper
03.02.26
2026 02 03 17 34 Trendjumper Einführung
Zunächst inormieren wir unsere Stammkunden bezüglich des bevorstehenden Seminars und bieten für ... Mehr »